Literature DB >> 9447419

Relationship between CD4 count and CD4% in HIV-infected people.

L M Yu1, P J Easterbrook, T Marshall.   

Abstract

OBJECTIVE: To describe the relationship between absolute CD4 count and CD4%, and the influence on this of gender, risk group, age, a diagnosis of AIDS, use of zidovudine (ZDV) therapy and PCP prophylaxis.
METHODS: 9203 paired serial measurements of CD4 count and CD4% on 1017 initially AIDS-free and ZDV-naive HIV positive patients from a London-based cohort were available for analysis. Multi-level regression procedures were used on log-transformed data to relate values of CD4 count to a given level of CD4%. We estimated the effect of selected covariates on this relationship from the exponent of the covariate coefficient.
RESULTS: A strong linear relationship was found between log CD4 and log CD4%, CD4 = e 1.78(CD4%)1.26 or 5.93 (CD4%)1.26 (excluding covariates). Based on this model, a CD4% of 5%, 15%, and 30% corresponded to an estimated CD4 count (95% confidence interval [CI]) of 45 cells/mm3 (17-117 cells/mm3), 182 cells/mm3 (64-499 cells/mm3) and 438 cells/mm3 (132-1395 cells/mm3), respectively. However, after adjustment for selected covariates, the predicted CD4 count for a given CD4% was found to be lower among heterosexuals and injecting drug users as compared with homosexual men by 30% and 17% respectively; following an AIDS diagnosis by 21%; and after initiation of ZDV therapy and PCP prophylaxis by 19% and 10%, respectively.
CONCLUSION: This analysis should be useful to clinicians and researchers in relating values of CD4 count to CD4%, although we have demonstrated that this is not a simple relationship. The wide CI observed in the estimated CD4 count particularly at high CD4% values, and the adjustments necessary according to risk group, following an AIDS diagnosis and use of ZDV and PCP therapy limit its application in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447419     DOI: 10.1093/ije/26.6.1367

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  6 in total

1.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings.

Authors:  Rami Kantor; Lameck Diero; Allison Delong; Lydia Kamle; Sarah Muyonga; Fidelis Mambo; Eunice Walumbe; Wilfred Emonyi; Philip Chan; E Jane Carter; Joseph Hogan; Nathan Buziba
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

2.  Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.

Authors:  Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland
Journal:  Clin Infect Dis       Date:  2007-08-13       Impact factor: 9.079

3.  Simultaneous Treatment of Missing Data and Measurement Error in HIV Research Using Multiple Overimputation.

Authors:  Michael Schomaker; Sara Hogger; Leigh F Johnson; Christopher J Hoffmann; Till Bärnighausen; Christian Heumann
Journal:  Epidemiology       Date:  2015-09       Impact factor: 4.822

4.  CD4 Count, Magnetic Resonance-white Matter Signals, and Magnetic Resonance Spectroscopy in Human Immunodeficiency Virus Patients.

Authors:  M A Hashmi; Shyam Baboo; Bibhuti Saha
Journal:  J Neurosci Rural Pract       Date:  2018 Jul-Sep

5.  Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand.

Authors:  Somsak Akksilp; Opart Karnkawinpong; Wanpen Wattanaamornkiat; Daranee Viriyakitja; Patama Monkongdee; Walya Sitti; Dhanida Rienthong; Taweesap Siraprapasiri; Charles D Wells; Jordan W Tappero; Jay K Varma
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

6.  Population-based CD4 counts in a rural area in South Africa with high HIV prevalence and high antiretroviral treatment coverage.

Authors:  Abraham Malaza; Joël Mossong; Till Bärnighausen; Johannes Viljoen; Marie-Louise Newell
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.